Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01185639
Recruitment Status : Completed
First Posted : August 20, 2010
Results First Posted : November 29, 2019
Last Update Posted : November 29, 2019
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
This protocol is a single arm phase II multi-center trial evaluating the efficacy of Stereotactic Body Radiation Therapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) with response or stable disease after 4 cycles of first-line chemotherapy. The core hypothesis tested is that SBRT after 4 cycles of first-line chemotherapy is feasible, safe, provides durable local control of treated lesions and improves time to progression compared to historical controls. Patients are eligible for enrollment if they have metastatic NSCLC with ≤5 lesions amenable to SBRT.

Condition or disease Intervention/treatment Phase
Non-Small-Cell Lung Carcinoma Liver Cancer Adrenal Cancer Radiation: stereotactic body radiation therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Stereotactic Body Radiation Therapy (SBRT) After First-Line Chemotherapy for Metastatic NSCLC
Actual Study Start Date : August 2010
Actual Primary Completion Date : June 27, 2016
Actual Study Completion Date : June 27, 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SBRT for metastatic NSCLC
SBRT for lung lesions, liver lesions, adrenal lesions, spinal lesions
Radiation: stereotactic body radiation therapy
For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
Other Names:
  • Elekta Bodyframe
  • Cyberknife

Primary Outcome Measures :
  1. Progression-free Survival [ Time Frame: up to 2 years ]
    Actuarial progression-free survival will be determined using the product-limit method of Kaplan and Meier and will be reported with an exact 95% confidence interval. Using the RECIST criteria including progression of the protocol treated tumors, non-protocol treated tumors and the development of new metastatic disease. Only protocol treated tumors will be determined by RECIST defined as complete lesion disappearance or <25%or original size; partial >30% decrease of target lesion; stable <30% decreased of target lesion and; local failure increase >20% of target lesion. Non-protocol tumor progression will be determined by the treating physician. Measured by imaging every 3 months.

Secondary Outcome Measures :
  1. To Assess Physical Function for This Cohort of Patients [ Time Frame: up to 3 months after treatment ]
    Using the Vulnerable Elders Survey (VES-13) A 13-item self-reporting questionnaire includes age, self-rated health, limitations in physical function and disability to assess for deterioration of physical function/health. Scoring for the VES-13 is as follows: Total scores are summed together based on self-rated health (0-1), physical function (0-2), functional disability (0-4), (range from 0 to 7). A total score of 3 or more identifies participants as vulnerable to the risk of decline of physical function.

  2. Number of Participants With Local Control [ Time Frame: up to 2 years ]
    Local control (LC) of SBRT-treated lesions will only be assessed in patients with at least 4-months of radiographic follow-up.

  3. Overall Survival [ Time Frame: up to 4 years ]
    Overall survival will be reported with an exact 95% confidence interval.

  4. Impact of Treatment on Quality of Life (FACT-L) [ Time Frame: up to 3 months after treatment ]
    Using the Functional Assessment of Cancer Therapy - Lung (FACT-L) a 36-item self-administered questionnaire evaluating physical, social/family, emotional, and functional well-being; subscales (symptoms, cognitive function, regret of smoking) on a five-point scale from 0 (not at all) to 4 (very much). Maximum score 136. Subscale scores added to obtain total score. The higher the score the greater the impact on the quality of life.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  • Patients with AJCC sixth edition metastatic non-small cell lung carcinoma
  • Pathologic diagnosis of stage 4 non-small cell lung cancer prior to enrollment.
  • Patients must have response or stable disease by RECIST criteria after 4 cycles of first-line chemotherapy
  • Maximum of number of lesions per patient will be 5 total. .
  • Patients with solitary brain metastases previously treated with surgery or stereotactic radiosurgery (+/- WBRT) and currently controlled at the time of study enrollment are also eligible. Patients with history of brain metastases must have an MRI showing no active brain metastases within 80 days of study enrollment. Patients with a history of brain metastases may have up to 5 extracranial sites of disease except for those with an untreated primary tumor where section will also apply.
  • Patients with newly diagnosed stage IV NSCLC with an untreated primary must no more than 3 active extracranial metastatic lesions other than the primary site and regional lymph nodes.
  • Age ≥ 18 years old
  • Performance Status 0-2 (ECOG)
  • A signed study specific consent form is required.

Lung (only applies to patients with active lung lesions)

  • Patients cannot have more than 3 lung lesions
  • Local failure after surgical resection will be consider a metastatic lesion for purposes of protocol inclusion.
  • All lung lesions must be visible on CT imaging
  • Cumulative diameter of lung lesions must be <7cm
  • Patients may have active mediastinal disease in a single mediastinal nodal station if he/she has not received prior mediastinal RT
  • Must meet criteria regarding status of primary tumor site described in section 3.1.9.
  • Must be able to anticipate achieving SBRT dosimetry guidelines
  • Must have adequate lung function defined within 90 days of enrollment as: (1) Forced Expiratory Volume in 1 second (FEV1) >30% of predicted or >800 Ml, (2) diffusing capacity of the lung for carbon monoxide (DLCO) >30 % predicted and (3) no evidence of actively worsening respiratory status

Liver (only applies to patients with active liver lesions

  • Patients cannot have more than 3 liver lesions
  • All active liver lesions must be discrete on CT or MRI imaging
  • Combined diameter of all liver lesions must be <6cm
  • Must be able to anticipate achieving SBRT plan per dosimetry guidelines for the liver.
  • Liver function tests (AST, ALT, total bilirubin) should be within ≤ 3 times the upper limit of normal (ULN)
  • Serum Albumin must be >2.5g/dL
  • Patients cannot have active ascites.

Adrenal Gland

  • Unilateral adrenal disease
  • Must be able to anticipate achieving the SBRT plan per dosimetry guidelines.

Bone Lesions

  • Treatment of any bone lesion is permissible if it is anticipated that the dosimetry guidelines can be met.

Spine and Paraspinal lesions

  • Patients cannot have more than 3 vertebrae or paraspinal sites involved (each involved vertebral body or paraspinal site is scored as 1 site of disease)
  • Must be no clinical or radiographic evidence of spinal cord compression
  • If spinal metastases is within previously irradiated field, there must be a 6 month interval between prior radiation course and study enrollment
  • Prior spinal cord maximum dose at level of vertebral disease must be ≤50Gy

Exclusion Criteria:

  • Primary tumor progression on first-line chemotherapy
  • Patients with complete response to first-line chemotherapy with no measurable target for SBRT
  • >5 metastatic lesions or >3 metastatic lesions in patients with an untreated primary site are ineligible (ipsilateral hilar and mediastinal lymph nodes are considered part of an untreated primary site and are not counted as metastatic lesions)
  • Solitary brain metastases and an untreated node positive primary tumor, without other extracranial metastases amenable to SBRT are ineligible
  • Retreatment of previously irradiated tumor will be excluded per above.
  • Mediastinal lymph nodes involving multiple mediastinal nodal stations or N3 disease are ineligible.
  • Pleural effusion known to be malignant or visible of chest xray.
  • Untreated brain metastases
  • Bilateral adrenal metastases
  • Metastases in other sites not considered amenable to SBRT
  • Patients with liver metastases cannot have received prior upper abdominal radiation
  • Prior radiation to spine (most commonly in treatment of primary lung cancer), cannot have received >50Gy to the spinal cord at the level of current vertebral metastases
  • Clinical or radiographic evidence of spinal cord compression are ineligible
  • Patients with serious, uncontrolled, concurrent infection(s).
  • Weight loss (>10% of body weight) in the prior 3 months.
  • Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01185639

Layout table for location information
United States, North Carolina
Coastal Carolina Radiation Oncology
Wilmington, North Carolina, United States, 28401
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
Sponsors and Collaborators
Wake Forest University Health Sciences
Layout table for investigator information
Principal Investigator: William Blackstock, MD Wake Forest University Health Sciences
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences Identifier: NCT01185639    
Other Study ID Numbers: IRB00013994
NCI-2010-01877 ( Registry Identifier: CTRP )
CCCWFU 62110 ( Other Identifier: Wake Forest University Health Sciences )
First Posted: August 20, 2010    Key Record Dates
Results First Posted: November 29, 2019
Last Update Posted: November 29, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Wake Forest University Health Sciences:
lung cancer
Stereotactic body radiation therapy
bone cancer
Spinal Column
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Adrenal Gland Neoplasms
Neoplasms by Site
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Endocrine Gland Neoplasms
Adrenal Gland Diseases
Endocrine System Diseases